anti-CD20 CAR-T in vivo assay


We have successfully developed various animal models for the in vivo assay of anti-CD 20 CAR-T cell therapy. Immunodeficiency mice are injected intravenously, subcutaneously, or intraperitoneally with CD20+ cells, such as lymphoma cell lines, CD20 transfected cell lines, human primary lymphoma cells, as well as customized cell lines to build up a murine B-cell malignancy model. Rat and non-human primate (NHP) models can be provided as well.